A5013502385- Cancer-related gene regulation
- Epigenetics and DNA Methylation
- Fibroblast Growth Factor Research
- Conferences and Exhibitions Management
- Histone Deacetylase Inhibitors Research
- Heterotopic Ossification and Related Conditions
- Renal and related cancers
- TGF-β signaling in diseases
- Connective tissue disorders research
Mayo Clinic
2020
WinnMed
2020
Mayo Clinic in Arizona
2018
Bone-stimulatory therapeutics include bone morphogenetic proteins (e.g. BMP2), parathyroid hormone, and antibody-based suppression of WNT antagonists. Inhibition the epigenetic enzyme enhancer zeste homolog 2 (EZH2) is both anabolic osteoprotective. EZH2 inhibition stimulates key components bone-stimulatory signaling pathways, including BMP2 cascade. Because high costs adverse effects associated with use, here we investigated whether dosing can be reduced by co-treatment inhibitors....
Sunday PostersEx-4 treatment was found to enhance the expression of Cx43 in pre-osteoblastic MC3T3-E1 cells.Immunofluorescence staining demonstrated upregulated Ex-4treated cells.Moreover, lucifer yellow dye transfer assay aided comparison gap junctional intercellular communication Ex-4-treated cells compared with control group.In cells, induction dependent on glucagon-like peptide 1 receptor (GLP-1R), as it abolished by a GLP-1R antagonist pretreatment.Osteoblast differentiation evaluated...